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inhibitors (SSRIs) were the most commonly used subgroup of antidepressant 
drugs in both countres (63.88% and 73.76% in Finland and Serbia in 2010, 
respectively) which is in accordance with a current clinical practice guidelines. 
Eight drugs fell under DU90% segment in both observed countries, but the share 
of utilization of antidepressants differed between countries. Sertraline was the 
most commonly used in Serbia (47.73%), while citalopram and escitalopram 
accounted for the highest share in Finland (25.43% and 17.11%, respectively). 
CONCLUSIONS: The large differences in utilization of antidepressants between 
observed countries implies possible underdiagnosing of affective disorders in 
general practice. The differences are partly consequence of different 
socioeconomic and health policy factors among the selected countries. To reduce 
the serious consequences that may be caused on that way, the early diagnosis 
and timely, adequate and effective management and treatment of depression is 
essential. Acknowledgement: This work is supported by Ministry of Education 
and Science, Republic of Serbia, project No. 41012.  
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OBJECTIVES: Psychotropic drugs have been associated with an increased risk of 
falls, particularly when used by seniors. Unintentional falls are the leading cause 
of injury-related hospital admissions among seniors. This study examines the 
use of three psychotropic drug classes: benzodiazepines and related drugs, 
antidepressants and antipsychotics. METHODS: Claims level data from the 
National Prescription Drug Utilization Information System (NPDUIS) Database 
were analyzed for seniors on public drug programs in six Canadian provinces 
between 2001-2002 and 2009-2010. This analysis looked at trends in selected 
psychotropic drug use, including use by age and sex, and a comparison of use in 
community and long-term care settings. Within each class, trends in use of 
chemical subgroups were examined. RESULTS: The age–sex-standardized rate of 
selected psychotropic drug use increased slightly during the study period, from 
32.1% in 2001–2002 to 33.5% in 2009–2010. The use of antidepressants and 
antipsychotics increased, while benzodiazepine use among seniors decreased. In 
2009–2010, the rate of selected psychotropic drug use was 74.9% among nursing 
home residents, compared with 34.0% among non–nursing home residents. The 
rate of selected psychotropic drug use decreased with age among seniors in 
nursing homes but increased with age among those not in nursing homes. 
CONCLUSIONS: Further investigation of the use of these drugs in seniors is 
required, particularly among older seniors and seniors living in nursing homes, 
where rates of use are particularly high. The risks associated with these selected 
psychotropic drugs are of particular concern in seniors, who are already at 
heightened risk of adverse events due to the number of drugs they are taking, 
their higher prevalence of certain chronic conditions, and age-related changes in 
the body.  
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OBJECTIVES: Use of atypical antipsychotics for conditions such as conduct 
disorder, depression, ADHD, and Tourette’s syndrome in children is highly 
prevalent; however, efficacy has not been proven in clinical trials. A DHHS letter 
to state Medicaid directors expressed concern over the use of antipsychotics in 
children and initiated steps to increase its safe, effective and appropriate use. 
This study examined the level of evidence available in claims to support atypical 
antipsychotic use in Mississippi Medicaid children and young adults. METHODS: 
A retrospective analysis was conducted using the Mississippi Medicaid claims 
data from 2008-2011. Pharmacy and medical claims files were linked using 
beneficiary ID. Prescriptions, included only if the beneficiary was below 21 years 
of age on the day of the claim, were classified as to whether a diagnosis to 
support the use of the drug appeared in medical claims within one year of the 
prescriptions and whether diagnoses that were in the claims were supported by 
evidence ratings provided in Micromedex. RESULTS: The 7,487 beneficiaries 
eligible for the study accounted for a total of 107,544 prescriptions for 
antipsychotics. 75.6% of these prescriptions could not be associated with an 
identifiable mental illness diagnosis from the medical claims. Of the 26,164 
prescriptions that were associated with a diagnosis, about 53% of the 
prescriptions were supported by evidence. Among the other 47%, which were not 
supported by evidence, depression, bipolar disorder and mental retardation were 
the most common diagnoses. CONCLUSIONS: It appears that some antipsychotic 
use in this population may not be supported by evidence and/or prescribers are 
reluctant to record mental health diagnoses. Since most of these prescriptions 
required prior authorization, diagnoses were provided but do not appear in the 
medical claims. The lack of supporting diagnoses in medical claims is a 
significant limitation when examining the use of antipsychotics among children.  
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OBJECTIVES: There is a dearth of real-world information on preschoolers with 
attention-deficit/hyperactivity disorder (ADHD) and few ADHD medications are 
approved for children under age 6. This study sought to identify characteristics 
and treatment patterns of preschoolers with ADHD, compare preschoolers to 
older children, and assess conformity with preschooler treatment guidelines 
which recommend behavioral interventions prior to pharmacotherapy. 
METHODS: Medicaid beneficiaries with an ADHD diagnosis (ICD-9 314.0x) in 
2010, continuous enrollment 12 months pre/post the earliest diagnosis (‘index’), 
and a confirmatory diagnosis were identified in the Truven Health MarketScan® 
Multi-State Medicaid Database. Preschool (age 4-5), school-age (6-11), and 
adolescent (12-18) cohorts were based on age at index. Age cohorts were 
compared on patient characteristics, behavioral health services, and prescription 
drug claims using MarketScan Treatment Pathways. RESULTS: The sample 
(10,347 preschoolers; 70,101 school-age children; 43,347 adolescents) was 
predominantly male. Significantly (p<0.001) more preschoolers had learning 
disabilities and hearing disorders (16%, 12%) than school-age children (12%, 6%) 
and adolescents (5%, 4%). Depression and anxiety rates increased significantly 
with age from 4% and 6% in preschoolers to 18% and 10% in adolescents. 
Methylphenidate and amphetamine salt combinations were the main ADHD 
medications across all cohorts, but preschoolers were less likely to receive long-
acting formulations. Dextroamphetamine, clonidine, and guanfacine utilization 
was higher in preschoolers; atomoxetine and lisdexamphetamine utilization was 
higher in older children. Within 30 days of diagnosis, 54% of newly-diagnosed 
preschoolers filled an ADHD medication prescription versus 62% school-aged 
children and 58% adolescents (p<0.001). Corresponding behavioral health 
services rates were 29%, 26% and 34% (p<0.001). CONCLUSIONS: Most children 
with ADHD are treated with medication; predominant medications differ by age 
group. In contrast to treatment guidelines suggesting preschoolers try behavioral 
interventions before medication, over half of newly-diagnosed preschoolers 
filled ADHD prescriptions within a month of diagnosis but less than a third 
incurred behavioral health services.  
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OBJECTIVES: Antipsychotic medications are the primary pharmacologic 
treatment for schizophrenia. This study characterized the outpatient medication 
treatment patterns for schizophrenia from 2003-2010 in the United States. 
METHODS: Data from the National Ambulatory Care Survey (NAMCS) and the 
National Hospital Ambulatory Medical Care Survey (NHAMCS) for 2003-2010 were 
pooled and weighted to provide national level estimates. Schizophrenia was 
identified using the ICD-9 code 295.xx. The data contained information on 3,211 
visits for schizophrenia, representing 22.3 million outpatient visits in the United 
States during 2003-2010. Using procedures that reflected the multistage sampling 
of the surveys, representative estimates were made for patient and physician 
characteristics, payer type, and medication use patterns. RESULTS: Most 
schizophrenia visits were covered by Medicare (35.7% [31.2%-40.4%]) and 
Medicaid (35.2% [31.4%-39.2%]) rather than private insurance (13.1% [10.5%-
16.1%). Antipsychotics were prescribed at most visits (78.8% [75.1%-82.1%]), 
including antipsychotic polypharmacy at 21.5% [18.4%-25.1%] of visits, second-
generation antipsychotic (SGA) monotherapy at 45.3% [41.5%-49.2%] of the visits, 
and first-generation antipsychotic (FGA) monotherapy at 11.9% [9.6%-14.7%] of 
visits. The most commonly used antipsychotics were risperidone (25.1% [21.8%-
28.7%]), olanzapine (22.7% [19.7%-26.0%]), and quetiapine (16.5% [12.8%-20.9%]). 
Quetiapine was most strongly associated with antipsychotic polypharmacy 
(55.4% [44.8%-65.6%]) and concomitant use of anticonvulsants (38.0% [25.7%-
52.1%]), sedatives (44.5% [32.5%-57.2%]), and antidepressants (55.5% [42.6%-
67.7%]). Risperidone (23.2% [16.7%-31.2%]) and FGAs (35.8% [29.6%-42.6%]) were 
associated with highest rates of anticholinergic use. Rates of polypharmacy, FGA 
monotherapy, and SGA monotherapy did not change significantly across the 
study period (p = 0.396). CONCLUSIONS: Meaningful differences exist between 
outpatient visits for different antipsychotics in terms of antipsychotic 
polypharmacy, concomitant psychotropic, and non-psychotropic medications. 
This analysis demonstrates the utility of the NAMCS and NHAMCS data for 
investigating disease states and their treatment patterns.  
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OBJECTIVES: To examine the difficulty using services reported by caregivers of 
children aged 3-17 years with ASD as compared to caregivers of children with 
other developmental disorders (DD) and mental health conditions (MHC). 
METHODS: A cross sectional study was conducted using the 2009-2010 National 
Survey of Children with Special Health Care Needs (NS-CSHCN) (N = 18,702). 
Difficulty using services was assessed as issues with: eligibility, availability, 
getting appointments, cost, and obtaining information. Chi-square analyses and 
separate binomial logistic regressions were conducted to compare likelihood of 
difficulty with all five measures across ASD, DD only, MHC only, and DD & MHC 
groups, after adjusting for socio-demographics, number of special children in the 
household, child’s functional ability, and presence of a physical condition. 
RESULTS: Majority of the sample were older children (6-17 years), Whites, 
caregivers with ≥200% FPL income and greater than high school education. 
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Sixteen percent (n = 3,025) of the caregivers had a child with an ASD diagnosis. 
As compared to caregivers of children with MHC only, caregivers of children with 
ASD were significantly more likely to report issues with availability (AOR = 2.16, 
95% CI = 1.66-2.82), information (AOR = 1.89, 95% CI = 1.46-2.45), eligibility (AOR = 
1.80, 95% CI = 1.38-2.37), cost (AOR = 1.67, 95% CI = 1.31-2.14), and appointments 
(AOR = 1.35, 95% CI = 1.09-1.68). When compared to the DD & MHC group, the 
ASD group was found to be significantly more likely to report issues with 
availability, obtaining information, and cost of services. CONCLUSIONS: ASD 
caregivers reported greater difficulty with all five service difficulty measures as 
compared to caregivers of children with MHC only. However, ASD group reported 
greater problems only in availability, obtaining information, and cost of services, 
when compared to DD & MHC group.  
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OBJECTIVES: To use administrative claims to examine geographic variation 
trends in ADD diagnostic prevalence, medication use and associated medical and 
pharmacy costs. METHODS: A retrospective design and descriptive analysis of 
continuously enrolled (medical and pharmacy benefits) commercial members 
aged four to 40 between January 1, 2008 and December 31, 2010 from 
MarketScan®Commercial Claims and Encounters dataset. Key metrics included 
percent of continuously enrolled patients with ADD diagnosis, patients with ADD 
medication use and associated pharmacy and medical costs per enrollee. ADD 
diagnosis was defined as having a medical diagnostic code (ICD9) of 3140 at any 
time during a given year. Medication use was defined as having at least one 
claim for amphetamines, attention-deficit/hyperactivity-disorder agents or 
stimulants. RESULTS: The datasets comprised of 11.8, 12 and 13 million enrollees 
in 2008, 2009 and 2010, respectively. Results indicate that although the diagnostic 
prevalence, medication use and associated medical and pharmacy costs were 
the highest in the South throughout the study period, Northeast region had the 
highest growth rate. Increasing by 34.1% from 1.9% to 2.5% for patients 
diagnosed and by 43.0% from 2.4% to 3.5% for patients treated with ADD 
medications. Growing at rate of 59.0% from $34.21 in 2008 to $54.39 in 2010, 
Northeast outpaced the other regions by more than 24.1% on ADD related 
medical and pharmacy spend per enrollee. CONCLUSIONS: Northeast is the 
fastest growing region for ADD diagnosis, medication use and related spend. 
Further research is warranted to examine the factors underlying this trend. The 
findings suggest consideration of utilization management programs and cost 
containment strategies to ensure appropriate access, patient safety and cost-
effective use of ADD medications.  
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OBJECTIVES: Bipolar disorder is a costly severe mental illness with high rates of 
hospitalizations compared to several other behavioral disorders. This study aims 
to compare all-cause and mental health-related hospitalizations among adult 
patients with bipolar disorder 6-months before and after initiating lurasidone, an 
atypical antipsychotic agent. METHODS: A retrospective analysis of health 
insurance claims from the Truven Health MarketScan Commercial Database was 
conducted. The study population included individuals ages 18–64, who initiated 
lurasidone between October 1, 2010 to September 30, 2011 (initiation date=index), 
had ≥ 1 inpatient or ≥ 2 outpatient medical claims with an ICD-9-CM diagnosis 
code for bipolar disorder and had continuous health benefit coverage during the 
study period. All-cause hospitalizations and mental health-related 
hospitalizations associated with a primary diagnosis code for a mental health 
disorder were evaluated for the 6-months pre- and post-index date. Proportions 
of patients with hospitalizations and mean number of hospitalizations were 
compared using chi-square and paired t-test, respectively. RESULTS: The study 
population (N=234) was predominantly female (68.8%) with a mean age of 41.6 
years. Common pre-index comorbidities included depression (61.5%), anxiety 
(24.4%), hypertension (20.5%) and diabetes (20.1%). The proportion of patients 
with all-cause hospitalizations decreased from 33.3% in the pre-period to 21.4% 
in the post-period (p = 0.0005). Similarly, the proportion of patients with mental 
health-related hospitalizations decreased from 27.8% to 17.1% between the pre-
and post-index periods (p=0.0006). The mean numbers of hospitalizations in the 
pre- and post-index periods were 0.6 and 0.3 for all-cause (p=0.0175) and 0.5 and 
0.2 for mental health-related conditions (p=0.0310). CONCLUSIONS: In this 
analysis of patients with bipolar disorder, significantly smaller proportions of 
patients were hospitalized for all-cause and mental health-related diagnoses in 
the 6 months after initiating lurasidone compared to the 6 months before 
initiation. The mean numbers of hospitalizations were also significantly lower in 
the 6-months after initiation on lurasidone.  
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OBJECTIVES: To investigate the use of health care utilizations and direct medical 
costs for patients with depression. METHODS: This study combined major 
clinical information of 1183 depressed patients who registered for the 
prospective depressed patients cohort study (CRESCEND: the Clinical Research 
Center for Depression Study) from January 2006 to August 2008 and the health 
insurance claims filed with the Health Insurance Review & Assessment Service, 
HIRA. Of these patients, 834 who had HAMD-17 scores > 14 at screen visit and 
more than one time claim for reimbursement of antidepressants at HIRA after 
their cohort enrollment were subject to this analysis on their use of health care 
institutions, in-patient and out-patient, as well as their medical costs. RESULTS: 
The hospital visit by out-patients with depression was 17.3 times a year with the 
average hospitalization rate at 20.9%. The times of hospital visits tended to 
increase in cases of elderly patients, patients with comorbidities, patients 
treated with combination therapy, patients prescribed with NADs and patients 
treated with multiple drugs in combination. The hospitalization rate tended to 
increase in cases of patients with comorbidities, severer patients in HAMD 
scores, patients treated with combination therapy, Patients prescribed with 
NADs and patients treated with multiple drugs in combination. In direct medical 
costs, drug expenses represented 60.6%. The costs tended to increase in elderly 
patients, patients with comorbidities, severer patients in HAMD scores, 
combination therapy patients, patients prescribed with NADs than SSRI and 
patients prescribed with multiple drugs. Drug expenses increased with the rise 
in out-patient visits, and medical costs at 12 months increased in out-patients 
with less hospital visits. CONCLUSIONS: SSRIs are first-line treatment to save 
direct medical costs. HAMD is regarded as the most relevant measure not only 
for the severity of depression but also for the estimation of the use of health care 
institutions and medical costs.  
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OBJECTIVES: Buprenorphine/naloxone combination (BUP/NAL) is recommended 
in the treatment of opioid dependence. Clinical guidelines do not specify the 
minimum duration of treatment required to achieve long-term remission. This 
study evaluated the impact of treatment persistence on health care charges. 
METHODS: Study was conducted on a US insurance claims database. It included 
patients initiating treatment with BUP/NAL claim between November 2006 and 
December 2011, not previously treated with buprenorphine, with at least one 
repeat claim after 30 days. Discontinuation was defined as absence of BUP/NAL 
claim for 90 days. Health care charges over 12 months were compared between 
persistent and non-persistent patients, adjusting on baseline characteristics 
(demographics, comorbidities, treatment, and resource utilization before index 
date). RESULTS: Of 19,008 patients with an incident claim of BUP/NAL, 35.7% 
appeared to be short-term users and were excluded. Among the remaining 
12,231 patients, the average duration of follow-up was 12.9 months, and 2846 
were followed for at least two years. The probability of continuing treatment 
over 24 months was 40.9%. Patients under 25 years old, with a diagnosis of 
hepatitis or soft tissue infection were more likely to discontinue. Patients treated 
for at least 12 months had lower mean total charges compared to non-persistent 
patients ($22,912 vs. $31,687; p<0.0001), adjusting on baseline characteristics. 
Among non-persistent patients, total charges per quarter reached a maximum 
during the first trimester following discontinuation (+91% compared to period 
from 6 to 4 months before discontinuation, p<0.0001), and were also significantly 
higher in the second trimester after discontinuation (+52%, p=0.0003), compared 
with before discontinuation. Main drivers of excess charges were hospitalization 
and outpatient visits. Majority of long-term users of BUP/NAL discontinued 
treatment before 24 months. CONCLUSIONS: Non-persistence was associated 
with higher charges and evidence was consistent with a causal relationship 
between discontinuation and increased charges. Treatment persistence 
improvement may lead to cost savings.  
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OBJECTIVES: To evaluate if the Iowa Medicaid duloxetine depression Prior 
Authorization (PA) policy, implemented may 24, 2010, inadvertently increased 
atypical antipsychotic use in depressed patients. We compare initiations of 
duloxetine and other relevant medications for depression in Iowa before  
and after PA implementation and in Missouri, which had no duloxetine  
PA. METHODS: Using de-identified Iowa and Missouri Medicaid claims data 
(1999-2010), two cohorts were selected from each state: 2010 policy change 
cohort (index date: 5/24/2010) and 2009 control cohort (index date: 5/24/2009). 
Patients had to have ≥1 inpatient or 2 other medical claims with a depression 
diagnosis pre-index; ≥1 antidepressant or antipsychotic claim during the  
